Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment

Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (2012) NICE guideline CG151

Colorectal cancer (2012) NICE quality standard 20

Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (2012) NICE technology appraisal guidance 242

Colorectal cancer: the diagnosis and management of colorectal cancer (2011) NICE guideline CG131

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (2010) NICE technology appraisal guidance 212

Capecitabine for the treatment of advanced gastric cancer (2010) NICE technology appraisal guidance 191

Cetuximab for the first-line treatment of metastatic colorectal cancer (2009) NICE technology appraisal guidance 176

Cetuximab for the treatment of head and neck cancer (2008) NICE technology appraisal guidance 145

Laparoscopic surgery for the treatment of colorectal cancer (2006) NICE technology appraisal guidance 105

Improving outcomes in head and neck cancers (2004) NICE cancer service guidance

Improving outcomes in colorectal cancer (2004) NICE cancer service guidance

Capecitabine and tegafur with uracil for metastatic colorectal cancer (2003) NICE technology appraisal guidance 61